NEW YORK (GenomeWeb) – Pathway Genomics has signed an agreement to make its next-generation sequencing-based clinical genetic tests available in Mexico through health services provider Salud Interactiva, the companies announced today.
Specific terms of the deal were not disclosed.
Pathway sells a variety of NGS assays including ones for diet and weight loss, circulating tumor DNA mutations, hereditary cancer, and carrier screening, as well as metabolic response for commonly prescribed medications.
"Our research determined that the wide range of tests that Pathway offers are at the forefront of the genetic revolution we are seeing in healthcare today that is driving the trend towards predictive medicine," Salud Interactiva CMO and COO Eduardo CÃ rdenas said in a statement. "Physicians and users within our network will now have affordable access to information about how their own genetic blueprint impacts their health."
About a year ago, Pathway announced that it had partnered with G-TAC and Sony subsidiary M3 to market a number of its tests in Japan.